漳州片仔癀药业股份有限公司2025年半年度报告摘要

Core Viewpoint - The company has approved a mid-term profit distribution plan, proposing a cash dividend of 14.00 yuan per 10 shares, amounting to a total of 844,644,094.00 yuan, which represents 58.56% of the net profit attributable to shareholders for the reporting period [1][15][17]. Group 1: Company Overview - The company is identified as Zhangzhou Pianzaihuang Pharmaceutical Co., Ltd. with the stock code 600436 [2]. - The company held its seventh supervisory board's 23rd meeting on August 28, 2025, to review and approve the half-year report and profit distribution plan [2][5]. Group 2: Financial Data - The company reported a net profit attributable to shareholders of 1,442,309,309.94 yuan for the first half of 2025 [17]. - The undistributed profits of the parent company as of June 30, 2025, were 10,393,498,872.57 yuan [17]. Group 3: Profit Distribution Plan - The proposed cash dividend is 1.40 yuan per share (including tax) [16]. - The total number of shares as of June 30, 2025, was 603,317,210, which will be used as the basis for the dividend distribution [17]. - The profit distribution plan was approved unanimously by the board and supervisory board, with no votes against or abstentions [5][20][21]. Group 4: Decision-Making Process - The 2024 annual shareholders' meeting authorized the board to decide on the profit distribution plan for 2025 [19]. - The board meeting held on August 28, 2025, resulted in a unanimous approval of the mid-term profit distribution plan [20]. - The supervisory board also reviewed and approved the plan, confirming it aligns with legal regulations and does not harm shareholders' interests [21].